Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03356561 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
A Phase 1 study of Healthy, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT03356561: Completed Phase 1 study of Healthy, sponsored by Janssen Vaccines & Prevention B.V..
NCT03356561 is a Phase 1 study of Healthy that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 100 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03356561, a Phase 1 study of Healthy, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of Ad26.ZIKV.001 at 2 dose levels, 5\*10\^10 viral particles (vp) and 1\*10\^11 vp, administered intramuscularly as single dose and as 2-dose schedules in healthy adults.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.ZIKV.001 5*10^10 vp
- BIOLOGICAL Ad26.ZIKV.001 1*10^11 vp
Study Locations (2)
Kansas
- Johnson County Clinical Trials - Lenexa
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-11-26 |
| Est. Completion | 2019-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03356561
The ClinicalTrials.gov registry entry for NCT03356561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03356561 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03356561 about?
NCT03356561 is a clinical study titled "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers". The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of Ad26.ZIKV.001 at 2 dose levels, 5\*10\^10 viral particles (vp) and 1\*10\^11 vp, administered intramuscularly as single dose and as 2-dose schedules in healthy adults.
What is the current status of trial NCT03356561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2017-11-26. Estimated completion is 2019-09-23.
What conditions does trial NCT03356561 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT03356561?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.ZIKV.001 5*10^10 vp (BIOLOGICAL), Ad26.ZIKV.001 1*10^11 vp (BIOLOGICAL).
Who is sponsoring clinical trial NCT03356561?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03356561 being conducted?
This trial has 2 study locations across Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.